BIOGEN IDEC INC. : Biogen Idec's Commitment to MS Demonstrated Through …4-tradersKey scientific highlights being presented during ECTRIMS from the company's pipeline will include analyses of pooled data from the Phase 3 DEFINE and CONFIRM cli…
Data from the Biogen Idec MS PipelineVictoria Times ColonistKey scientific highlights being presented during ECTRIMS from the company's pipeline will include analyses of pooled data from the Phase 3 DEFINE and CONFIRM clinical trials of oral dimeth…
Biogen Idec's Commitment To MS Demonstrated Through Significant Scientific …TheStreet.com (press release)… include analyses of pooled data from the Phase 3 DEFINE and CONFIRM clinical trials of oral dimethyl fumarate (BG-12), primary results fr…
Biogen Idec's Commitment to MS Demonstrated Through Significant Scientific …MarketWatch (press release)About DAC HYP Daclizumab high-yield process (DAC HYP) is a subcutaneous formulation of daclizumab in late-stage clinical development for the tr…
Seattle Genetics Will Get Undisclosed Milestone PaymentsEquities.comThe phase II randomized, open-label study is designed to evaluate the safety and efficacy of ADCs anti-CD22 (DCDT2980S, RG7593) and DCDS4501A (RG7596) each in combination with Rituxan
Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody …DailyFinanceThe phase II randomized, open-label study is designed to evaluate the safety and efficacy of ADCs anti-CD22 (DCDT2980S, RG7593) and DCDS4501A (RG7596) each in combin…
VIDEO: Clinical Exercise Testing in ME/CFS Research & TreatmentProHealthOther presentations on YouTube (not in English) were: • “B-lymphocyte depletion as a therapeutic intervention for chronic fatigue syndrome/ME” by the rituximab trial rese…
Pick Biotech Winners Like A Pro: John McCamantSeeking AlphaThat would be a huge leg up for the stock, at another 100 points. TLSR: And the B-cell lymphomas are a great trail to follow. JM: Exactly. When Rituxin [rituximab] was in development, it was a …
Roche Faces New Foe as Boehringer Plans a Rituxan CopyBloombergRituxan, also know by its generic name rituximab, had 6 billion Swiss francs ($6.45 billion) in sales last year. Roche's patents on the medicine expire in 2018 in the U.S. and earlier i…
Swiss Stocks Extend 19-Month High After US Jobs ReportBloombergLonza Group AG (LONN) slipped 2.6 percent to 49.29 francs. Lonza and Teva Pharmaceutical Industries Ltd. are still evaluating the path forward for a phase III trial of its rituximab generic…